Clinical Scorecard: FDA expands treatment in nephrotic syndrome
At a Glance
Category
Detail
Condition
idiopathic nephrotic syndrome
Key Mechanisms
characterized by urinary protein loss leading to low blood albumin levels and potential complications such as high cholesterol, infections, and blood clots that may obstruct small blood vessels.
Target Population
adult and pediatric patients aged 2 years and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome in remission
Care Setting
clinical trial setting
Key Highlights
Obinutuzumab approved to reduce relapse risk in nephrotic syndrome
Efficacy assessed in a phase 3 randomized open-label multicenter controlled trial with 85 patients
73% of patients on obinutuzumab met primary efficacy endpoint
Common side effects include infections and neutropenia
Obinutuzumab previously approved for certain cancers and lupus nephritis
Guideline-Based Recommendations
Diagnosis
Diagnosis of idiopathic nephrotic syndrome requires normal urine protein levels and absence of swelling.
Management
Obinutuzumab administered intravenously on specified days for treatment.
Monitoring & Follow-up
Monitor for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
Risks
Potential complications include infections, infusion-related reactions, and neutropenia.
Patient & Prescribing Data
patients aged 2 years and older with frequently relapsing or steroid-dependent idiopathic nephrotic syndrome
Obinutuzumab shows a statistically significant improvement in maintaining remission compared to standard-of-care treatment.
Clinical Best Practices
Ensure patients are in complete remission before initiating obinutuzumab treatment.
Educate patients about potential side effects and the importance of monitoring.
